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Summary The use of a somatostatin analogue (SMS 201-995) has greatly facilitated the treatment of patients
with the midgut carcinoid syndrome. Clinical studies have shown that SMS reduces the peripheral levels of
tumour-produced serotonin (5-HT) and tachykinins, e.g. neuropeptide K (NPK), basally and after pentagast-
rin provocation. Some studies have indicated an inhibitory effect of SMS on tumour cell growth as well. In the
present study we have investigated the effects of SMS on four different human midgut carcinoid tumours
maintained in long term culture. Media levels of 5-HT and NPK-LI in tumour cell cultures decreased rapidly
during incubation with SMS (10-8-10-'OM) in all four tumours studied without evidence for tachyphylaxis
(up to 6 weeks observation period). SMS treatment (10-8 M) during 4 days reduced the media concentrations
of 5-HT by 56%, while the intracellular contents of 5-HT were decreased by 27% indicating dual inhibitory
effects on synthesis and secretion of 5-HT from tumour cells. The DNA contents of cultures were not affected
by SMS (10-8M or 10-` M) treatment for 4 or 14 days. When tumour cell cultures were challenged with
isoprenaline (IP) (10-6 M) no reduction of the IP induced release of 5-HT could be detected after pretreatment
of tumour cell cultures with SMS (10-8 M) for 1 h, 4 h or 4 days. These studies provide evidence for a direct
action of the somatostatin analogue on midgut carcinoid tumour cells, reducing both synthesis and secretion
of hormones from tumour cells. This effect appears not to be related to inhibition of tumour cell growth. The
inhibition of 5-HT secretion from tumour cells by SMS seems to operate via a second messenger system
different from the one mediating the 1-adrenoceptor stimulated release of 5-HT.
The use of a somatostatin analogue (octreotide, Sando-
statinR, SMS 201-995) has greatly facilitated the clinical treat-
ment of patients with the midgut carcinoid syndrome (Kvols
et al., 1986; Vinik & Moattari, 1989; Gorden et al., 1989). In
clinical studies the somatostatin analogue has been shown to
reduce the levels of tumour-produced serotonin (5-HT) and
tachykinins, e.g. neuropeptide K (NPK), in peripheral blood
under basal conditions and after pentagastrin (PG) provoca-
tion (Ahlmann et al., 1988a; Oberg et al., 1989). Hemo-
dynamic studies have demonstrated that octreotide rapidly
stabilises arterial blood pressure during carcinoid crisis des-
pite high circulating levels of 5-HT, indicating a peripheral
site of action as well (Kvols et al., 1985; Ahlman et al.,
1988a). Using a model with intraocular heterotransplants of
human midgut carcinoid tumours to immunosuppressed rats
we have previously demonstrated a significant reduction of
the P-adrenoceptor mediated release of 5-HT from these
tumours after systemic treatment of the host animals with
octreotide (Ahlund et al., 1989b). However, in those studies
the effect of the drug may theoretically have been conveyed
via receptors on tumour vessels and/or on the tumour cell
surface. In order to investigate the effects of the somatostatin
analogue on isolated tumour cells, we have studied growth
and secretion of 5-HT and NPK from cultured human mid-
gut carcinoid tumour cells subjected to octreotide treatment.
The biochemical response to treatment with octreotide, stud-
ied by urinary levels of 5-hydroxyindoleacetic acid (5-HIAA)
and by levels of 5-HT in peripheral whole blood during PG
provocation, were also monitored in the clinical situation.
Material and methods
Clinicalprovocation with pentagastrin
A provocation test using PG (0.6 jg kg- ' i.v.) was used
(Ahlman et al., 1985; Oberg et al., 1989). The levels of 5-HT
in peripheral whole blood were determined under basal con-
ditions and 1, 3, and 5 min after injection of PG. The pro-
voked release of 5-HT was expressed as the ratio between the
highest level after injection and the mean basal level of 5-HT
(peak/basal ratio ref. < 1.40).
Tumour material and clinical histories
Tumour material was obtained from mesenteric lymph node
metastases of four consecutive patients with primary ileal
carcinoids showing argyrophilic and argentaffin silver stain-
ing properties. Tumour biopsies obtained at surgery were
transported to the tissue culture laboratory in cold tissue
culture medium (RPMI 1640, Northumbria Biologicals Ltd,
Cramlington, UK). All the patients had metastatic carcinoid
disease with elevated levels of 5-HT in peripheral blood and
high urinary excretion of 5-HIAA.
Case I Female, age 60, had bilateral hepatic metastases.
The urinary 5-HIAA levels at referral were 300tsmol 24 h-'
and the peak/basal ratio of 5-HT levels in peripheral whole
blood at PG provocation were 1.50 (basal level 590 ng ml-').
After treatment with SMS (100 fig x 2 s.c.) for 4 weeks this
ratio was reduced to 1.08 (basal level 218 ngml', ref.
< 160). The preoperative 5-HIAA levels during SMS treat-
ment were mol 24 h-'. She underwent surgical debulk-
ing and two subsequent hepatic arterial embolisations leading
to a state of biochemical normalisation with 5-HIAA levels
of 12ttmol 24 h-' (ref. <70). Two years post-embolisation
on continuous treatment with SMS (100 lig x 1 s.c.) this
patient still has 5-HIAA levels within the normal range.
Case II Male, age 59, had mesenteric lymph node metas-
tases and localised retroperitoneal tumour masses, but no
demonstrable hepatic spread. The 5-HIAA levels at referral
were 117 jsmol 24 h-' and the peak/basal ratio of 5-HT levels
in peripheral blood at PG provocation were 1.63 (basal level
204 ng ml-'). Under protection with SMS he underwent
radical surgical removal of the lesions. After surgery, SMS
treatment was cessated and the postoperative 5-HIAA levels
were then normal (51 Lmol 24 h-') and so was the PG test
with a peak/basal ratio of 1.19 (basal level 115 ng ml- '). Two
years after surgery this patient still has normal radiological
and biochemical findings.
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Case III Female, age 68, with bilateral hepatic metastases
and peritoneal carcinoidosis. The patient had been surgically
explored abroad with 5-HIAA levels of 156 gimol 24 h-' and
was thereafter treated with SMS (100lsg x 2 s.c.). Three
months later she was referred to our unit and had by then
5-HIAA levels of 120tLmol 24 h-' and a peak/basal ratio of
5-HT levels at PG provocation of 1.04 (basal level 256 ng
ml-'). After surgical debulking and two subsequent hepatic
arterial embolisations the 5-HIAA levels were reduced to
18 jsmol 24 h-'. Ten months after completion of these proce-
dures and continued treatment with SMS (100 tLg x 1 s.c.)
her 5-HIAA levels are still within the normal range.
Case IV Male, age 45, with unilobar hepatic metastases.
The 5-HIAA levels at referral were 176ILmol 24 h-' and the
peak/basal ratio of 5-HT levels at PG provocation was 1.48
(basal level 276 ng ml-'). Under protection with SMS he
underwent two operations (removal of the primary tumour
and metastatic lymph nodes followed by hemihepatectomy),
leading to normal 5-HIAA levels (18 gLmol 24 h-'). One year
after completion of the surgical treatment this patient still
has normal radiological and biochemical findings.
Cell cultures
Non-fibrotic parts of the tumours were minced into 1-2 mm
pieces and incubated with 0.2% collagenase (type I, Sigma,
St. Louis, MO) with the addition of 350gll 0.004% DNAase
(type I, Sigma)/25 ml collagenase solution. Incubation was
carried out at 37°C for 60 min with continuous oxygenation.
Cell suspensions were filtered, centrifuged at 175 g for 5 min,
washed and centrifuged twice in RPMI 1640. solution to
remove collagenase. Aliquots (I ml) of the final tumour cell
suspensions were seeded on collagen-coated (Collagen type I,
Collaborative Research, Lexington, MA) tissue-culture plates
(1.9 cm2). Cell suspensions were carefully mixed before seed-
ing to achieve an even cell density in all wells. However, the
seeding densities varied slightly between different experi-
ments, but were always kept between 105 and 106 cells per
well. RPMI 1640 culture medium was supplemented with 4%
heat-inactivated foetal calf serum, L-glutamine (5 mM), trans-
ferrin (5figml-'), insulin (5 ILg ml-'), penicillin (200 IU ml-')
and streptomycin (200gtg ml-'), and incubated at 37°C in a
90%-humidified atmosphere with 20% 02 and 5% CO2.
Tumour cells were grown for 9-13 weeks and media were
changed every 3-4 days. Samples of culture media were
withdrawn regularly and assayed for 5-HT and NPK-like
immunoreactivity (NPK-LI).
Determination of5-HT
Aliquots (10 yl) of culture medium, or peripheral blood after
hemolysis and protein precipitation (cf. Ahlman et al., 1985),
were injected onto the column of an HPLC system with
electrochemical detection to determine 5-HT. Standard
curves were made by injecting standard solutions of 5-HT
(5-hydroxytryptamine-creatininesulfate, Sigma) in 10JLl of
0.1 M perchloric acid (Ponzio & Jonsson, 1978).
Assay ofNPK-LI
Tachykinins other than substance P were determined by
radioimmunoassay using antiserum K12 as previously de-
scribed (Theodorsson-Norheim et al., 1985). Using the cross-
reactivity to neurokinin A (NKA) as the 100% reference, the
crossreactivity to kassinin was 84%, eledoisin 30%, NKB
26% and NPK 61%. The major immunoreactive component
measured by antiserum K12 in media from cultured carcinoid
cells is NPK, and NPK-LI will, therefore, subsequently be
used to denote the immunoreactive material. In plasma and
extracts of tumour tissue antiserum K12 detects NKA,
NKA-sulphoxide, NKA (3-10) and NKA (4-10) and an
eledoisin-like peptide (Theodorsson-Norheim et al., 1985;
Norheim et al., 1987).
Assay ofDNA
Cultured tumour cells were sonicated in Tris-LiCl and stored
at - 20°C until assay. The fluorochrome Hoechst 33258 was
added to the samples and DNA-concentrations were measur-
ed spectrophotometrically (Labarca & Paigen, 1980).
Statistical methods
Given values are mean ± s.e.m. and for significance testing
we have used unpaired t-test, two tailed.
Experimentalprotocol
Cell cultures of the four tumours (cases I-IV) were incu-
bated with SMS 201-995 (Sandoz, Basel, Switzerland) after
4-6 weeks of primary culture. Culture media were changed
every 3-4 days and replaced with fresh media containing
SMS. During experiments medium concentrations of 5-HT
and/or NPK-LI were followed at regular intervals and com-
pared with control cultures in standard medium.
Six experimental protocols were used:
Protocol I Tumour cell cultures (case I) were incubated
with two different concentrations of SMS (10°- M or 10-8 M)
during a 2-week period and then allowed to recover for 3
weeks (Figure 2).
Protocol 2 Tumour cell cultures (case II) were incubated
with SMS 10"M for 2 weeks, followed by SMS 10-9M for
2 weeks, and finally by SMS 10-8 M for another 2 weeks.
Tumour cells were then allowed to recover for 1-2 weeks
(Figure 3).
Figure 1 Fluorescence micrographs showing human midgut car-
cinoid tumour cells (case IV) in culture. Tumour cells are strongly
labelled by serotonin antibodies a, and tachykinin antiserum b.
The fluorescent material is concentrated to the cytoplasm of
tumour cells. Bar indicates 20rum.SOMATOSTATIN ANALOGUE AND CARCINOID TUMOUR 25
Protocol 3 Tumour cell cultures (case III) were incubated
with SMS 10-8 M or the SMS vehicle in the same dilution
(acetic acid 2mg, sodium acetate trihydrate 2mg, sodium
chloride 7 mg and 1 ml of sterile water) for 5 weeks. Addi-
tion of the diluted vehicle did not affect the pH of the culture
media (Figure 4).
Protocol 4 Tumour cell cultures (case III) were incubated
with SMS 10-1"M or I0- M during 2 weeks and the DNA
contents in the cell cultures were determined at the end of the
experiments (Table I).
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Figure 2 Medium levels of 5-HT a, and NPK-LI b, after incuba-
tion of tumour cell cultures (case I) with SMS at two different
concentrations: 10-8 M (0) or 10-1 M (U). Both concentrations
caused a significant (P<0.01) decrease in 5-HT levels compared
with untreated controls (0). The higher concentration also caus-
ed a significant reduction in NPK-LI levels (P<0.05). Values are
given as mean ± s.e.m., n = 9.
Protocol 5 Tumour cell cultures (case III) were incubated
with SMS 10-8 M for 4 days. At the end of the experiments
the cultures were sonicated and the intracellular contents of
5-HT and DNA were determined (Figure 5).
Protocol 6 The P-adrenoceptor induced release of 5-HT was
studied in tumour cell cultures (cases III and IV) after short-
term incubation (5 min) with isoprenaline (IP) 106 M. These
cultures were pretreated with SMS 108 M for 1-4 h, or for 4
days (Figure 6).
Microscopy
Tumour cell cultures were examined and photographed at
regular intervals using a phase contrast microscope (Nikon-
Diaphot). The presence of 5-HT and tachykinins in tumour
cells were studied by immunofluorescence. Cell cultures were
fixed in 4% paraformaldehyde in PBS (pH 7.4) and incubat-
ed with anti-5-HT antibodies (1:200 YC 5/45 HKL; Sera-Lab
Ltd, Crawley Down, Sussex, UK) or tachykinin antiserum
NKA2 1: 500 (Brodin et al., 1986). Antibody binding sites
were visualised using a biotin-streptavidin system (Vector
Lab, Burlingame, CA). Controls included substitution of the
specific antiserum for normal serum of corresponding species.
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Figure 3 Medium levels of 5-HT a, and NPK-LI b, after incuba-
tion of tumour cell cultures (case II) with SMS 201-995 in
increasing concentrations during three successive 2-week periods.
SMS treatment cultures (0) had significantly lower levels of both
5-HT and NPK-LI (P<0.05) compared with untreated controls
(0). Values are given as mean+s.e.m., n = 9-27.
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Figure 4 Medium levels of 5-HT after incubation of tumour cell
cultures (case III) with SMS 201-995 (10-8 M) (0) or the SMS
vehicle) (0). SMS caused a significant decrease in 5-HT concent-
rations (P<0.05). Both groups showed an interesting cyclic
variation in 5-HT levels. Values are given as mean±s.e.m.,
n = 12.
Table I Effect of SMS treatment during 2 weeks on 5-HT in medium
and DNA contents of human midgut carcinoid tumour cells in
culture
DNA contents 5-HT in medium Ratio
(rig well) (nmol1-') S-HT.:DNA
(A)
Controls 5.44±0.66 757±64.5 170.5± 10.2
SMS 10-10M 5.10±0.74 641±18.4 154.8±20.8
(B)
Controls 17.4± 1.5 2221 ±95.1 133.6± 7.2
SMS 10 M 17.5±0.90 1477± 118.9a 85.8±7.8a
Values are given as mean±s.e.m., n = 12; aP<0.001.
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Figure 5 Tumour cell cultures (case III) were incubated with
SMS 201-995 (10-1 M) during 4 days. The levels of 5-HT in the
medium a, and intracellular 5-HT b, as well as the DNA contents
in the cultures c, were studied. When SMS treated cultures ( _ )
were compared with untreated cultures ( E1), even this short
period caused a significant (P<0.001) reduction of both the
medium levels and the intracellular levels of 5-HT. The DNA
contents increased over 4 days, but was not affected by SMS
treatment. Values are given as mean ± s.e.m., n = 6-24.
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Figure 6 a, Tumour cell cultures (case III) were stimulated with
isoprenaline (IP 10-6 M) 1 (0) or 4 days (0) after change of
media. The cells stimulated 4 days after media change had signi-
ficantly higher media levels of 5-HT, but the release pattern of
5-HT upon IP stimulation was very similar. Pretreatment with
SMS (10-8 M) (O) for 4 days kept the basal levels of 5-HT low
but did not affect the release after IP stimulation. Values are
given as mean ± s.e.m., n = 8-24. b, Tumour cell cultures (case
IV) were stimulated with IP (10-6 M) 1 h (0) or 4 h (U) after
change of media and addition of SMS (10-8 M) and were com-
pared with unstimulated controls (O 1 h, 0 4 h). The IP stimu-
lated release was not prevented by SMS. Values are given as
mean±s.e.m., n = 4-8.
Results
Influence ofSMS 201-995 on the levels of5-HTand NPK-LI
and on the DNA contents oftumour cell cultures.
Cultured tumour cells from all four patients were positively
labelled with 5-HT antibodies and the tachykinin antiserum.
Intense labelling was observed over the cytoplasm of tumour
cells (Figure 1).
Incubation of tumour cells with two different concentra-
tions of SMS (10-10 M or 10-8 M) for a 2-week period (proto-
col 1) caused a marked decrease in the 5-HT levels in culture
media. Treatment with SMS 108M, but not 10-ioM, also
caused a significant (P<0.05) reduction in the levels of
NPK-LI. Two weeks after cessation of SMS treatment the
levels of 5-HT and NPK-LI in culture media were similar to
those in untreated controls (Figure 2a,b).
Tumour cells, incubated with increasing concentrations of
SMS (10-'0 M-I0-I M) during three successive 2-week periods
(protocol 2), maintained the concentrations of 5-HT and
NPK-LI at a low level compared with non-treated controls.
Even 2 weeks after the test period tumour cell culture media
had significantly lower levels of 5-HT than controls, while the
levels of NPK-LI did not differ. At the end of the observa-
tion period the 5-HT levels of controls were still high while
the NPK-LI levels were much reduced (Figure 3a,b).
Tumour cells incubated with SMS 10- M over 5 weeks
(protocol 3) showed much lower 5-HT levels than tumour
cells incubated with the SMS vehicle alone during the entire
stimulation period. Both groups showed a cyclic variation
(with 15 day cycles) of 5-HT levels in the media, as pre-
viously observed in long-term cultures (Ahlund et al., 1989a).
No signs of densensitisation to SMS were noted (Figure 4).
Incubation of tumour cell cultures with SMS (10-10M or
10-8 M) during 2 weeks (protocol 4) resulted in significantly
decreased 5-HT levels compared with untreated controls.
However, the DNA contents were very similar in treated and
non-treated groups (Table I). Cells from the same tumour
were seeded at two different cell densities. A constant, but
low, number of fibroblasts were demonstrated in all cultures.
The ratio of 5-HT concentration in culture media over DNA
contents of the two types ofcultures did not differ. However,
this ratio was clearly suppressed by SMS treatment (Table I).
Tumour cell cultures from case III were also treated with
SMS (10-8 M) during 4 days (protocol 5). Even this short
treatment significantly reduced the media levels of 5-HT, as
well as the intracellular levels of 5-HT, detected after sonica-
tion of the cultures. The DNA contents in these experiments
were also similar in treated and non-treated cultures (Figure
5a,b,c).
Influence ofSMS 201-995 on P-adrenoceptor induced release
of5-HT
Tumour cell cultures from case III were stimulated with IP
(10-6 M) 1 or 4 days after change of media. In both situa-
tions a pronounced release of 5-HT was demonstrated. How-
ever, the cells studied after 4 days had significantly higher
media levels of 5-HT. Pretreatment with SMS 10-8 M for 4
days kept the basal 5-HT concentration in the media at a
similar level as at onset of the experiment. The release of
5-HT upon IP stimulation (10-6 M) was, however, similar to
untreated controls (Figure 6a).
Tumour cell cultures from case IV (protocol 5) also show-
ed a pronounced release of 5-HT with IP (10-6 M) after
pretreatment with SMS I0O- M for 1 or 4 h. Sole incubation
with SMS 10-8 M during these time periods had no effect on
the 5-HT levels (Figure 6b).
Discussion
Somatostatin was originally characterised as a peptide hor-
mone (14 amino acids) inhibiting the release of growth
hormone in the hypothalamus (Brazeau et al., 1973). How-
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ever, somatostatin occurs widely in the CNS and in the
gastro-enteric-pancreatic endocrine system. it has been
ascribed a role as physiological regulator of secretion, e.g. it
inhibits the secretion of pancreatic and gut hormones and
exocrine secretion as well (Reichlin, 1983). Bauer et al. (1982)
synthesised an analogue (SMS 201-995) of the conforma-
tionally stable part of somatostatin (eight amino acids),
which was highly resistant to degradation and selective in its
inhibition of growth hormone secretion. This compound has
become a most valuable medical adjunct in the treatment of
several pancreatic and gut endocrine tumours due to its
suppression of hormone overproduction (Lamberts et al.,
1987a; Lamberts et al., 1990).
In the present study we have obtained evidence for a direct
effect of SMS on human midgut carcinoid tumours in cul-
ture. In all four tumours studied SMS reduced the media
levels of both 5-HT and NPK-LI in cultures of human
midgut carcinoid tumour cells within 4 days. The reduction
appeared to be stable during the period of study and was
similar at the two concentrations tested. In one experimental
protocol (2) control tumour cells were observed over 90 days.
The low media levels of NPK-LI at the end of this period
contrasted with well maintained levels of 5-HT. This finding
might indicate that the synthesis and secretion of peptides
and amines have different control mechanisms. Such differ-
ences are evident in the response to stimulation with P-
adrenoceptor agonists, i.e. 5-HT being released without
changes of tachykinin levels (Ahlman et al., 1988b). In these
experiments pretreatment of tumour cells with SMS did not
significantly inhibit the P-adrenoceptor induced release of
5-HT, tested after pretreatment up to 4 days. This is in
contrast to the clinical situation, where treatment with SMS
for 4 days reducts both the basal and provoked levels of
5-HT (Ahlman et al., 1988a). Case I in this series had
decreased levels of both urinary 5-HIAA (63%) and basal
5-HT in peripheral blood (63%) accompanied by an extin-
guished release reaction to PG after 4 weeks of treatment
with SMS. Case II had decreased 5-HIAA levels (23%) and
no release reaction upon PG provocation after 3 months of
treatment. Both these patients underwent similar treatment
with surgical debulking, liver ischemia and continuous SMS
treatment leading to a long-lasting state of biochemical
normalisation. Sole treatment with SMS in the carcinoid
syndrome had not been reported to reduce 5-HIAA levels
into the normal range of any patients (Gorden et al., 1989).
Case II and IV underwent uneventful major surgical proced-
ures under protection with SMS according to a previously
reported program (Ahlman et al., 1988a) resulting in total
remission of disease radiologically as well as biochemically.
PG has previously been shown not to cause release of
5-HT from human midgut carcinoid tumour cells in vitro
(Nilsson et al., 1985). In vivo there is strong experimental
evidence that PG acts via an indirect mechanism causing
release of catecholamines from the adrenals, in turn acti-
vating P-adrenoceptors located on enterochromaffin cells (or
carcinoid tumour cells) (Gronstad et al., 1987). Previous
studies using autoradiography and in vitro binding assay
have shown saturable and high affinity receptors with speci-
ficity for somatostatin on several different human endocrine
tumours (Reubi et al., 1987a,b; Lamberts et al., 1990). Our
findings indicate that SMS, presumably bound to receptors
on the midgut carcinoid tumour cells, inhibits the secretion
of tumour products via a second messenger system different
from the one mediating the P-adrenoceptor stimulated release
of 5-HT. The discrepancy between the blocked PG response
seen clinically and the unaffected release of 5-HT at P-
adrenoceptor stimulation seen in vitro (e.g. Case III) may
indicate that SMS also reduces the PG induced release of
catecholamines from the adrenal medulla. Alternatively, the
,B-adrenoceptor mechanism may operate via a modified
tumour receptor, since the IP-induced release from tumour
cell cultures cannot be blocked by P-adrenoceptor antagonists
(Ahlman et al., 1988b). However, immunocytochemically,
midgut carcinoid tumour cells display a positive reaction with
an antiserum directed against the ,B-adrenoceptor protein
(Wangberg et al., 1990). The decreased intracellular levels of
5-HT after short-term (4 days) treatment with SMS, in com-
bination with unchanged DNA contents, may indicate a
suppressed synthesis of 5-HT as well. In the present study we
have confirmed our previous observations (Ahlund et al.,
1989a) on a cyclicity of 5-HT secretion from cultured car-
cinoid tumour cells (Figures 2 and 4). Parallel changes in the
secretion of NPK-LI were also observed (Figure 2) and SMS
treatment did not abolish the cyclicity. Since the assays were
done in separate laboratories and at different times a tech-
nical error is less likely. Periodic induction ofenzyme systems
by local production of certain factors cannot be excluded.
Naturally occurring somatostatin appears to be an endo-
genous growth inhibitor, which delays the separation of
centrosomes indicative of the GI phase (Mascardo & Sher-
line, 1982). With the recent development of potent somato-
statin analogues a certain interest has been focused on the
inhibition of growth of experimental tumours in animal
models i.e. rat chondrosarcomas (Reubi, 1985), mice osteo-
sarcoma (Cai et al., 1986), acinar pancreatic carcinoma in
rats (Redding & Schally, 1984), prolactin-secreting pituitary
carcinoma in rats (Lamberts et al., 1986), and mammary,
prostate and ductal pancreatic carcinomas in rats (Cai et al.,
1986). Several mechanisms have been proposed e.g. inhibition
of the local production of growth factors, inhibition of
growth hormone and somatomedin C, specific binding to
tumour cell receptors with subsequent interference of intra-
cellular signals, or inhibition of the effects of oncogene
products (cf. Lamberts et al., 1987a; Schally, 1988). The
antiproliferative effect of somatostatin was studied by Mas-
cairdo and Sherline (1982) on two different cell lines and was
found to be effective in the range 10- -I0- M, coupled with
the physiological inhibition of secretory processes. Previous
experiments on cell cultures from an oestrogen-induced,
transplantable rat pituitary carcinoma have demonstrated an
inhibitory effect of SMS (10-9 M) on both basal and somato-
medin C-stimulated secretion of prolactin and on cell proli-
feration (Lamberts et al., 1986). Somatostatin was further
compared with two analogues in the inhibition of prolifera-
tion of a human breast cancer cell line and maximal effects
were observed at the 10-9 M concentration.
In the present experiments the DNA contents of human
midgut carcinoid tumour cells were studied after 4 days or 2
weeks of incubation with SMS (10O- and 10-0M). Within
these periods of time the SMS treatment had caused a pro-
nounced reduction of the media levels of 5-HT without any
observable effect on the DNA contents of the tumour cell
cultures. In the phase contrast microscope tumour cells
treated with SMS could not be distinguished from untreated
cells, and the density of tumour cells appeared unchanged.
The reduction in 5-HT levels observed during SMS treatment
is therefore most likely due to an inhibition of hormone
secretion, and possibly reduced hormone synthesis, from the
tumour cells rather than unchanged release from a reduced
number of tumour cells. In clinical studies on patients with
the midgut carcinoid syndrome, using SMS treatment, anti-
proliferative effects have been reported only in few patients in
large series (Soquet et al., 1987; Ahlman et al., 1991; Gorden
et al., 1989) in line with the present experimental findings.
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